| pubmed-article:2111867 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2111867 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:2111867 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:2111867 | lifeskim:mentions | umls-concept:C0033567 | lld:lifeskim |
| pubmed-article:2111867 | lifeskim:mentions | umls-concept:C0038838 | lld:lifeskim |
| pubmed-article:2111867 | lifeskim:mentions | umls-concept:C0038954 | lld:lifeskim |
| pubmed-article:2111867 | lifeskim:mentions | umls-concept:C0442805 | lld:lifeskim |
| pubmed-article:2111867 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:2111867 | lifeskim:mentions | umls-concept:C0075812 | lld:lifeskim |
| pubmed-article:2111867 | lifeskim:mentions | umls-concept:C0205355 | lld:lifeskim |
| pubmed-article:2111867 | pubmed:issue | 20 | lld:pubmed |
| pubmed-article:2111867 | pubmed:dateCreated | 1990-7-3 | lld:pubmed |
| pubmed-article:2111867 | pubmed:abstractText | The permanent survival rate of endotoxemic rats was studied. In 40 untreated control rats the survival rate 7 days after the endotoxin administration was 33%. The survival rate was increased to 40% with recombinant human superoxide dismutase (r-HSOD), to 55% (p less than 0.05) with the prostacyclin analogue Taprostene and to 70% (p less than 0.01) with the combination of r-HSOD and Taprostene (20 rats for each treatment group). r-HSOD and Taprostene provide significant and permanent protection in rat endotoxic shock. | lld:pubmed |
| pubmed-article:2111867 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2111867 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2111867 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2111867 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2111867 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2111867 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2111867 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2111867 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2111867 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2111867 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2111867 | pubmed:issn | 0024-3205 | lld:pubmed |
| pubmed-article:2111867 | pubmed:author | pubmed-author:SchneiderJJ | lld:pubmed |
| pubmed-article:2111867 | pubmed:author | pubmed-author:MatthiesenTT | lld:pubmed |
| pubmed-article:2111867 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2111867 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:2111867 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2111867 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2111867 | pubmed:pagination | 1421-6 | lld:pubmed |
| pubmed-article:2111867 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:2111867 | pubmed:meshHeading | pubmed-meshheading:2111867-... | lld:pubmed |
| pubmed-article:2111867 | pubmed:meshHeading | pubmed-meshheading:2111867-... | lld:pubmed |
| pubmed-article:2111867 | pubmed:meshHeading | pubmed-meshheading:2111867-... | lld:pubmed |
| pubmed-article:2111867 | pubmed:meshHeading | pubmed-meshheading:2111867-... | lld:pubmed |
| pubmed-article:2111867 | pubmed:meshHeading | pubmed-meshheading:2111867-... | lld:pubmed |
| pubmed-article:2111867 | pubmed:meshHeading | pubmed-meshheading:2111867-... | lld:pubmed |
| pubmed-article:2111867 | pubmed:meshHeading | pubmed-meshheading:2111867-... | lld:pubmed |
| pubmed-article:2111867 | pubmed:meshHeading | pubmed-meshheading:2111867-... | lld:pubmed |
| pubmed-article:2111867 | pubmed:meshHeading | pubmed-meshheading:2111867-... | lld:pubmed |
| pubmed-article:2111867 | pubmed:meshHeading | pubmed-meshheading:2111867-... | lld:pubmed |
| pubmed-article:2111867 | pubmed:meshHeading | pubmed-meshheading:2111867-... | lld:pubmed |
| pubmed-article:2111867 | pubmed:meshHeading | pubmed-meshheading:2111867-... | lld:pubmed |
| pubmed-article:2111867 | pubmed:meshHeading | pubmed-meshheading:2111867-... | lld:pubmed |
| pubmed-article:2111867 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2111867 | pubmed:articleTitle | The prostacyclin analogue taprostene and recombinant human superoxide dismutase increase the permanent survival rate of endotoxemic rats. | lld:pubmed |
| pubmed-article:2111867 | pubmed:affiliation | Center of Research, Grünenthal GmbH, Aachen, FRG. | lld:pubmed |
| pubmed-article:2111867 | pubmed:publicationType | Journal Article | lld:pubmed |
